Given that ATF4 is upregulated by signals in the tumor microenvironment, such as hypoxia [12], and is closely correlated to angiogenesis and adaptation of cancer cells to hypoxia [25], inhibiting ATF4 might be especially attractive for treating OS patients. Here, ATF4 is linked to cancer.